http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CoinEx Research November 2024 Report: Trump Triumphs, Bitcoin Trumping
-
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
-
Immutable Debuts 'Perpetual Rewards' with RavenQuest at the Helm
-
Hitachi to supply Japan's first SF6-free 300 kV circuit-breakers to Chubu Electric Power Grid
-
Emirates NBD Partners with HireVue to Revolutionize Recruitment and Enhance Employee Experience
-
Q2 Metals Drills 188.6 M Grading 1.56% Li2O, including 26 Metres of 2.03% Li2O, at the Cisco Lithium Property, James Bay, Quebec, Canada
-
Avanza Fonder Appoints Northern Trust to Provide Integrated Trading Solutions
-
U.S. DoD Awards USEUCOM BPA to SES Space & Defense
-
Discover the CPT (iComPneT) Listing on XT
-
Discover the APX Listing on XT
-
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
-
On-Chain AI Enterprise Platform Atua AI (TUA) to Support Amazon Nova AI Models
-
On-Chain AI Enterprise Platform Atua AI (TUA) to Support Amazon Nova AI Models
-
AI NFT Platform Colle AI (COLLE) To Support Amazon Nova AI Models
-
Walmart Delivers Last-Minute Savings and Convenience with Holiday Grand Finale
-
Hitachi, NTT Com Successfully Demonstrate World's First Real-Time Data Synchronization Over 600 km Using Storage
Virtualization Technology and IOWN APN
-
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse L
-
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
-
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
-
Monster Energy's David Wise Claims Third Place in Men's Freeski Halfipe at the FIS World Cup at China's Secret Garden
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
-
HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
-
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-
Unlock Passive Income with Crypto-Affiliate Marketing
-
Over 3,000 local and global tech experts, academics and entrepreneurs joined inaugural AI Week hosted by Qatar Foundation's QSTP
-
Lisa Vanderpump Throws an Epic Grand Opening Party For Pinky’s by Vanderpump at Flamingo Las Vegas
-
Gensource Potash Corporation Announces Granting of Stock Options
-
Greenberg Traurig's Annette Jarvis Featured in Women in Workouts List
-
Golden Minerals Announces NYSE American Notice to Commence Delisting and Intended Transition to OTCQB Market
-
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
-
Zevra Therapeutics Announces Organizational Changes
-
Availability of Elior Group’s Universal Registration Document for fiscal 2023-2024
-
HII’s Ingalls Shipbuilding Undocks USS Zumwalt (DDG 1000)
-
Morningstar, Inc. Increases Quarterly Dividend to 45.5 Cents Per Share
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
-
Canadian Securities Exchange Welcomes Listing of HM Exploration Corp
-
South Coast AQMD Awards $109 Million to Advance Zero-Emission Infrastructure in Underserved Communities
-
Worksport ($WKSP) To Showcase Upcoming Innovations Live on FOX & Friends National TV
-
Worksport ($WKSP) To Showcase Upcoming Innovations Live on FOX & Friends National TV
-
TEAMSTERS TELL AMAZON: AGREE TO BARGAINING DATES BY DEC. 15
-
Get a Free ROG Ally With Your ASUS Laptops or Desktops Over CA$1,499 This Holiday Season in Canada!
-
SnapLogic Named a Visionary in the 2024 Gartner® Magic Quadrant™ for Data Integration Tools for Third Consecutive Year
-
GRAY MEDIA AND THE NATIONAL COLLEGIATE HOCKEY CONFERENCE TEAM UP TO BRING ELITE COLLEGE HOCKEY FREE OVER-THE-AIR TO VIEWERS ACROSS THE COUNTRY
-
1 BTC Lottery: FUJIYAMA TAP Launches Globally on Telegram - A New Gaming Experience Celebrating Mt. Fuji
-
The Results Are In: America’s Favorite Department Store is…JCPenney!
-
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting


